PARTNERING

Partnering Overview

Targeting unique disease-specific peptide HLA complexes is an essential input for filling immunotherapeutic drug discovery pipelines. Pure MHC’s business development plan makes it easy to partner with mutually favorable terms and creative flexibility to meet your specific corporate needs.  

With Pure MHC’s available suite of research tools, an expansive range of services are available to assist collaborators in answering research and development questions related to epitope validation, development, and therapeutic exploitation of their existing targets.

Partnering Opportunities

Pure MHC is currently seeking partnerships to:

 

Develop therapeutics to novel peptide targets in multiple internal discovery projects.
Current target discovery projects in oncology include:

  • Non-small cell lung cancer (NSCLC)
  • Acute myeloid leukemia (AML)
  • Ovarian cancer
  • Colorectal Cancer (CRC)
  • Breast Cancer
  • Melanoma
  • Glioblastoma

Current target discovery projects in autoimmunity include:

  • Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS)

Collaborate on novel target discovery programs for other oncology indications, infectious diseases, and autoimmune disorders with partners active in specific indications in those fields

 

Apply its extensive HLA expertise, proprietary tools, and intellectual property to companies seeking answers to discrete research questions on a contract research basis under the company’s Pure MHC Solutions Program.  Potential Pure MHC Solutions projects include: 

  • Validating partner epitopes
  • Identifying immunogenetic epitopes in gene therapy viral vectors or novel therapeutic proteins delivered as proteins or as part of gene therapy
  • Assisting with other related research collaborations such as (click for more information):
    • MHC peptide target discovery with live human pathogens
    • MHC peptide target discovery from complex antigen mixtures (from infections disease to autoimmunity and allergy)
    • MHC peptide vaccine target discovery
    • Drug or therapeutic effects on antigen presentation
    • PHIDR healthy tissue database screening
    • Non-human MHC immunopeptidome characterization

MHC peptide target discovery with live human pathogens

MHC peptide target discovery with live human pathogens.  Pure MHC Solutions leverages decades of combined experience to grow and either infect model cell lines or pulse antigen presenting cells in vitro with most BSL3 or below human pathogens including viruses, bacteria, and parasites. Additionally, Pure MHC Solutions can identify MHC peptide targets with infected primary tissue samples regardless of host species (e.g. mice, non-human primates, humans). Then using advanced immunopeptidomics, identify high confidence pathogen-derived MHC class I, MHC class II or non-classical MHC peptide targets. This enables rational vaccine design and potential therapeutics by narrowing down key antigens and epitopes that are presented to the immune system by MHC.

MHC peptide target discovery from complex antigen mixtures (from infections disease to autoimmunity and allergy)

MHC peptide target discovery from complex antigen mixtures – from infectious disease to autoimmunity and allergy. Pure MHC Solutions can take complex antigen mixtures such as bacterial lysates, cell extracts, or allergen extracts and use them to identify antigens presented by MHC class I or MHC class II in vitro. This enables rational vaccine design and potential therapeutics by narrowing down key antigens from complex protein mixtures that are presented to the immune system by MHC.

MHC peptide vaccine target discovery

MHC peptide vaccine target discovery. Pure MHC solutions can identify specific HLA peptides presented by cells treated with a variety of vaccines regardless of domain (infectious disease, oncology). Prototype vaccines can be demonstrated to induce MHC antigen presentation prior to clinical trials and T-cell testing.

Drug or therapeutic effects on antigen presentation

Drug or therapeutic effects on antigen presentation. Pure MHC Solutions can elucidate how drugs and immune therapies quantitatively and qualitatively alter, block, or enhance HLA antigen presentation to T cells. This information can be used to determine a drug’s potential efficacy, its mechanism of action, or to assist in defining the potency and tuning strategies for novel therapeutics.

PHIDR healthy tissue database screening

PHIDR screen. Pure MHC Solutions can use its Peptide HLA Immunotherapy Data Resource (“PHIDR”), which is a proprietary healthy tissue database and repository, to guide TCR-based immune therapies to disease-specific targets by eliminating HLA/peptide complexes found on healthy tissues reducing off-target effects before clinical trials.

Non-human MHC immunopeptidome characterization

Non-human MHC immunopeptidome characterization. Pure MHC Solutions can determine the immunopeptide repertoire of non-human MHC molecules from any species like non-human primates, mice, other vertebrates. These data serve as the basis of MHC/T-cell immunological studies in important animal models.

Collaboration Opportunities

Pure MHC’s available suite of research tools allows for an expansive range of services to assist collaborators in answering research and development questions related to epitope validation, development, and therapeutic exploitation of their existing targets.

Unique IP Positioning for Collaborative Partners

Pure MHC holds intellectual property rights on the manufacture of soluble HLA proteins used in a proprietary method of immunogenic epitope discovery and validation. Our business model is focused on the discovery and development of these epitope targets for use by our collaborators in their immunotherapeutic modalities of choice. Such modalities might include TCRs, CAR-Ts, antibody drug conjugates and bispecific antibodies, or T cell eliciting vaccines. The synergistic combination of Pure MHC’s targets in the context of our collaborators’ immunotherapeutic modality provides the opportunity for strong intellectual property protection without starting the patent clock prematurely and using up valuable patent life.

Collaborate with Pure MHC to achieve your corporate and scientific goals.